NCT05704530Recruiting
Liquid Biopsies in Esophageal Cancer
Personalized Multimodal Treatment for Resectable Esophageal Cancer by Detecting Minimal Residual Disease Using Circulating Tumor DNA: a Multicentric Prospective Study
Source: ClinicalTrials.gov · Last updated 1 Jun 2026
Brief summary (registry, in English)
Purpose of this study is to determine the value of liquid biopsies, e.g. testing of minimal residual disease (MRD) by using liquid biopsies to measure circulating tumour DNA (ctDNA) at diagnosis and during the multimodal and multidisciplinary curative-intent treatment of resectable esophageal cancer.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 248 (estimated)
- First submitted
- 19 Jan 2023
- Start date
- 29 Mar 2023
- Primary completion date
- 30 Dec 2028
- Lead sponsor
- Universitaire Ziekenhuizen KU Leuven
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT05704530
What you commit to
- Study type: Interventional
- Planned participants: 248
- From 29 Mar 2023 to the primary completion date, 30 Dec 2028
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous exposure to chemoradiation (prior to MDT)
- Treatment plan after MDT: neoadjuvant chemotherapy with no radiation or chemoradiation with definitive intent (surgery is not planned)
Other illness
- (Oligo)metastatic disease
- Other active malignancies
Other
- Histologically or cytologically confirmed diagnosis other than squamous cell carcinoma or adenocarcinoma (eg. neuroendocrine carcinoma, lymphoma…)
Who the study is looking for
- Male or female, age \> 18 years
- New diagnosis of esophageal cancer, pathologically confirmed squamous cell carcinoma (ESCC) or adenocarcinoma (EAC)
- Clinically staged - cT1-4 N0-2 M0 (local or locally advanced, resectable)
- Eligible for multidisciplinary treatment as assessed by MDT
- Able to provide informed consent (ICF) according to Good Clinical Practice and national/European regulations
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UZA Coordinator of this site? Confirm its status | Antwerp | Belgium | Recruiting |
| UZ Gent Coordinator of this site? Confirm its status | Ghent | Belgium | Recruiting |
| UZLeuven Coordinator of this site? Confirm its status | Leuven | Belgium | Recruiting |
| AZ Delta Coordinator of this site? Confirm its status | Roeselare | Belgium | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.